ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,385,903, issued on Aug. 12, was assigned to NantBio Inc. (Culver City, Calif.).
"RP182 compositions and methods" was invented by Patrick Soon-Shiong (Culver City, Calif.) and Kayvan Niazi (Culver City, Calif.).
According to the abstract* released by the U.S. Patent & Trademark Office: "Compositions and methods for domain-specific targeting of CD206 are presented in which selected agents bind to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206. In certain aspects of the inventive subject matter, binding is specific, leads to a conformational change of CD206, and will induce phagocytosis in tumor associated macrophages and/or M2 macroph...